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Neurosciences, McMaster University, Hamilton, ON, Canada, 5 Operational Stress Injury Clinic, Parkwood Institute, London, 
ON, Canada, 6 MacDonald Franklin Operational Stress Injury Research Centre, Lawson Research Institute, London, ON, 
Canada, 7 Department of Neuroscience, Western University, London, ON, Canada, 8 Department of Life Sciences, Texas 
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Background: Sleep disturbances are a hallmark of posttraumatic stress disorder (PTSD), 
yet few studies have evaluated the role of dysregulated endogenous melatonin secretion 
in this condition.
Methods: This study compared the sleep quality and nocturnal salivary melatonin profiles 
of Canadian Armed Forces (CAF) personnel diagnosed with PTSD, using the Clinician 
Administered PTSD Scale (CAPS score ≥50), with two healthy CAF control groups; 
comprising, a “light control” (LC) group with standardized evening light exposure and 
“normal control” (NC) group without light restriction. Participants were monitored for 
1-week using wrist actigraphy to assess sleep quality, and 24-h salivary melatonin levels 
were measured (every 2h) by immunoassay on the penultimate day in a dim-light (< 5 lux) 
laboratory environment.
Results: A repeated measures design showed that mean nocturnal melatonin 
concentrations for LC were higher than both NC (p = .03) and PTSD (p = .003) with no 
difference between PTSD and NC. Relative to PTSD, NC had significantly higher melatonin 
levels over a 4-h period (01 to 05 h), whereas the LC group had higher melatonin levels 
over an 8-h period (23 to 07 h). Actigraphic sleep quality parameters were not different 
between healthy controls and PTSD patients, likely due to the use of prescription sleep 
medications in the PTSD group.
Conclusions: These results indicate that PTSD is associated with blunted nocturnal 
melatonin secretion, which is consistent with previous findings showing lower melatonin 
after exposure to trauma and suggestive of severe chronodisruption. Future studies 
targeting the melatonergic system for therapeutic intervention may be beneficial for 
treatment-resistant PTSD.
Keywords: sleep disturbance, melatonin, post-traumatic stress disorder, dim light melatonin onset, 
circadian, saliva
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iNtRoDUCtioN
Degraded mental health remains prevalent and impactful in 
military personnel (1, 2), and has significant implications 
for operational readiness and force sustainability (3–5). 
Posttraumatic stress disorder (PTSD) is a chronic and 
disabling neuropsychiatric condition that develops in a 
subset of individuals after exposure to traumatic or extremely 
stressful events (6). According to the Diagnostic and 
Statistical Manual 5th Edition (DSM-5) criteria (7), PTSD is 
characterized by an array of affective, cognitive and attention 
disturbances, that manifest as four clusters of symptoms. By 
the very nature of their profession, military personnel can be 
exposed to traumatic stressors (i.e., combat, injury, witnessing 
suffering, and/or death) and consequently are at high risk for 
developing PTSD following war-zone deployment(s) (8–11). 
Effective prevention and treatment strategies for military-
related PTSD are hampered by a lack of understanding of 
the basic pathophysiologic mechanisms/markers across 
different stages of disease progression (12–14). Moreover, the 
management of treatment-resistant PTSD presents a complex 
clinical challenge (15, 16) and many patients may continue 
to endure a heavy symptom burden, even despite the best 
available treatments (17).
Sleep disturbances are considered hallmark symptoms of 
PTSD and may contribute significantly to the development 
and maintenance of PTSD (18). Indeed, sleep complaints 
remain the most common presenting symptoms and subjective 
complaints among people with PTSD (19). Healthy sleep is 
defined by predictable, sufficient restorative sleep (20). These 
needs are disrupted in combat-exposed soldiers and veterans 
with PTSD (21, 22). According to the DSM-5, sleep disturbance 
and recurrent trauma-content nightmares are core hyperarousal 
and re-experiencing symptoms of PTSD (23). About 70% of 
individuals with PTSD have co-occurring sleep problems, 
reporting greater trouble initiating and maintaining sleep, early 
morning awakening, nightmares, nocturnal panic attacks, and 
other parasomnias (24). Distressed awakenings and inability to 
return to sleep, with or without recalled trauma nightmares, may 
be the most common symptom motivating combat veterans to 
seek treatment for PTSD (22, 25).
Relevant preclinical and clinical literature has neglected 
the potentially important pathophysiological role of circadian 
rhythm disruption in PTSD (26). Despite considerable research 
examining the association between sleep and PTSD (27), few 
studies have attempted to identify specific underlying biological/
circadian mechanisms that may account for this relationship 
(28, 29). McFarlane et al. (30) found lower urinary melatonin 
levels after trauma exposure, predicting a higher risk for PTSD, 
while van Liempt et al. (31) reported undisturbed nocturnal 
plasma melatonin profiles in PTSD patients. Other evidence 
underscores a key function of the melatonergic system in 
sleep and chronodisruption following trauma exposure and its 
probable role in a chronically dysregulated circadian network in 
PTSD (26, 32).
For healthy individuals who sleep at night, daytime 
endogenous melatonin levels are barely detectable. Once the 
sun sets, melatonin production begins to rise with a peak near 
the midpoint of the dark interval (33). This phenomenon is 
called dim light melatonin onset (DLMO) (34). After sunrise, 
the nocturnal surge of melatonin ends; called melatonin offset 
(MelOff) (35, 36). Recent investigations have highlighted the 
ubiquitous influence of circadian timing and melatonin in 
almost all physiologic functions (35, 36). An altered sleep-
wake cycle has been correlated with physiological imbalances 
that are linked to the development of various mental disorders 
and melatonin-based chronobiologic interventions may 
prove efficacious for treatment of circadian disruption in 
PTSD (37–39). Moreover, mounting evidence suggests that 
strong antioxidant activities and diverse immunomodulatory 
properties of melatonin as potential protective roles in diverse 
neuropsychiatric disorders including PTSD (38, 40). The aim 
of the current research was to test the hypothesis that military-
related PTSD with clinically endorsed “sleep difficulties” is 
associated with decreased production of endogenous melatonin 
and possible chronodisruption, relative to healthy military 
controls. We investigated whether salivary melatonin levels 
and sleep patterns are different in Canadian Armed Forces 
(CAF) military personnel with PTSD when compared to 
matched healthy CAF members as controls, by assessing daily 
sleep quality for 7 days and measuring 24-h salivary melatonin 
secretion on the eighth day of study.
MateRiaLS aND MethoDS
Study Design
We conducted a retrospective cohort study investigating relationships 
between sleep disturbances and salivary melatonin levels in CAF 
military personnel with PTSD and matched healthy CAF members 
as controls.
Participants and Clinical Procedures
Volunteers included treatment-seeking CAF members (N = 7) 
with clinically endorsed “sleep difficulties,” aged 31 to 45 years 
with mean age and standard deviation of 37.57 ± 6.05. These 
participants had experienced a self-reported deployment-
related trauma with a “current” diagnosis of PTSD by a licensed 
CFHS (Canadian Forces Health Services) and/or Department of 
Veteran Affairs of Canada (VAC) psychiatrist. Each diagnosis was 
based upon a comprehensive psychiatric examination, according 
to criteria outlined by the Clinician Administered PTSD Scale 
(CAPS) for the DSM-5, including CAPS score ≥50 (41). Healthy 
CAF members (N = 14) who had not been diagnosed with any 
DSM-5 condition (including PTSD) at any point in their lives 
or reported sleep disorders, served as controls. Controls were 
stratified according to those whose data was collected under 
either naturalistic diurnal environmental conditions (NC; 
N = 7) aged 22 to 52, with mean age and standard deviation of 
35.25 ± 9.38 or idealized sleep-wake conditions with strictly 
controlled nocturnal light-exposure, as previously described 
(light controlled (LC); N = 7) aged 23 to 43 with mean age and 
standard deviation of 29.43 ± 8.50 (42). A comparison of all 
participants is presented in Table 1.
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Participants were excluded if they: a) reported current 
suicidal or homicidal ideation; b) met DSM-V criteria for current 
substance abuse or dependence (except nicotine or caffeine) per 
self-reported answers on the diagnostic interview; or c) met 
DSM-V criteria for a psychotic disorder; or d) were diagnosed 
with incapacitating cognitive impairment, traumatic brain 
injury; or e) were taking supplementary melatonin; or f) were 
on specific medications known to alter endogenous melatonin 
levels (e.g., beta blockers, methamphetamines or nonsteroidal 
anti-inflammatory drugs); and/or (g) recent shift work or 
transmeridian travel. Participants were asked to refrain from the 
use of alcohol for 24 h prior to participation in data collection.
This investigation protocol was approved by the Defence 
Research and Development Canada (DRDC) Human Research 
Ethics Committee (HREC; Protocol No. 2017-023) and adhered 
to the standards and regulations set forth by the Tri-Council 
Policy in accordance with the Ethical Principles for Medical 
Research Involving Human Subjects adopted in the Declaration 
of Helsinki. All participants provided written informed consent 
after a complete description of the study procedural details were 
explained to them and discussing any questions or concerns 
about the protocol. Participants were recruited between 2017 
and 2018 by DRDC—Toronto Research Centre (TRC) non-
physician research coordinator/staff through referrals by military 
physicians, mental health professionals, community clinics, and 
advertisements within Canadian Forces Bases (CFB) and/or 
through one of several Operational Stress Injury (OSI) clinics of 
the Department of Veterans Affairs Canada (VAC).
experimental Procedures
All participants wore a standard wrist activity monitor 
(Motionlogger version 14.000, Ambulatory Monitoring Inc., 
Amherst, NY, USA) for 7 days prior to the data collection to 
establish their baseline sleep hygiene. The actigraphic data were 
analyzed by the Cole-Kripke algorithm (43). Parameters assessed 
during the week prior to the 24-h data collection were daily 
bedtimes, arise times, time in bed (min), total wake minutes, 
total sleep minutes, sleep efficiency (%), Sleep LATency (SLAT), 
wake after sleep onset (WASO), and # of sleep episodes (see 
Supplementary Data Table 2). To assist scoring of the actigraph 
data all participants maintained a daily sleep log.
On the 8th day, all participants underwent a 24-h salivary 
melatonin assessment by providing 13 bi-hourly samples 
commencing at 0900 h and finishing at 0900 h the next day. All saliva 
samples were collected in very dim light (5 lux) since normal room 
lighting levels will suppress endogenous melatonin production. 
Each participant was assigned to a lounge chair for the entire 24-h 
data collection period. The subjects were allowed to get up from 
their chairs to access the washrooms or socialize for about 100 min 
of each 2-h block. However, they remained in ambient lighting 
levels of less than 5 lux throughout the 24-h data collection. All 
subjects returned to semi-recumbent posture in their lounge chairs 
at least 15 min prior to each sample. The saliva was collected in test 
tubes (Salivette®, Starstedt Inc. Montreal, QC). For each sample, the 
subjects chewed the cotton plug for 45 s, and then stopped chewing 
with the plug still in their mouth to allow the saliva to absorb for 
another 45 s. The participants were required to remain awake from 
0900 h until 2300 h, after which they were allowed to sleep. If asleep, 
they were awakened in the 15 min prior to the next sample. Meals 
were provided in three 1-h windows as follows: 1) lunch 12–13 h, 2) 
dinner 17–18 h, and 3) breakfast 07–08 h.
The saliva samples were analyzed for melatonin content 
using the Buhlmann Laboratories (Schönenbuch, Switzerland) 
enzyme-linked immunosorbent assay (ELISA) kits and used 
the Kennaway G280 anti-melatonin antibody. Each subject’s 
samples were analyzed in duplicate on the same ELISA plate. The 
reported intra- and inter-assay coefficients of variation for the 
kits were 12.6 and 22.9% respectively, with a limit of detection 
(sensitivity) of 0.5 pg/ml. Using the same melatonin collection 
protocol and melatonin ELISA, we compared the current 
melatonin and sleep findings to melatonin and sleep data from 
a cohort of seven military personnel while they were deployed 
to the most northerly manned outpost in the world (CFS Alert) 
during arctic summer (i.e., 24/7 sunlight) (42). This was the LC 
group. The PTSD group was assessed at Canadian Forces Base 
(CFB) Gagetown (Fredericton, New Brunswick). The normal 
control (NC) group were assessed at DRDC—TRC.
The distribution of military occupation specialties among 
the PTSD and healthy control groups are illustrated in 
Supplementary Data Table 1.
Of the seven PTSD participants, three were taking the 
sleeping medication zopiclone, one was taking lorazepam (an 
anxiolytic known to facilitate sleep), one was taking oxazepam 
(another anxiolytic known to facilitate sleep), and one was on 
both zopiclone and trazodone (an antidepressant known to 
facilitate sleep). Essentially, six of the seven PTSD participants 
were on medications to facilitate sleep (see Supplementary Data 
Table 1). None of the control participants (NC or LC) were on 
any medication. The gender split and age demographics of all 
three participant groups are illustrated in Table 1.
Statistical analyses
All demographic and clinical data in the tables are expressed as 
number and percentage of subjects [N (%)] or mean and standard 
deviation [mean (±SD)]. The mean (±SEM) salivary melatonin 
concentrations were compared using a “group” (PTSD vs. NC 
vs. LC) x “time of day” repeated-measures univariate analysis of 
variance (ANOVA) using the Geisser-Greenhouse correction 
for repeated measures. The mean (±SEM) of all sleep parameters 
were compared using a group x day repeated-measures univariate 
ANOVA to assess the effect of group and days and their interactions 
on each of the sleep parameters. Post hoc comparisons of significant 
effects in ANOVAs were performed using Newman-Keuls test. 
taBLe 1 | Demographic characteristics of study participants.
Group Sample size 
(N)
% Male Mean age ± SD 
(range)
PTSD 7 71.4 37.57 ± 6.05 (31–45)
NC 7 85.7 34.14 ± 9.55 (22–54)
LC 7 57.1 29.43 ± 8.50 (23–43)
PTSD, posttraumatic stress disorder; NC, normal controls; LC, light controlled.
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A p-value < 0.05 was considered statistically significant. Statistical 
analyses were performed using STATISTICA Software Version 
13, Palo Alto CA, USA.
ReSULtS
twenty-four hour Melatonin Production
The 24-h salivary melatonin secretion curves for all groups 
are shown in Figure 1. Overall, peak salivary melatonin 
concentrations (pg/ml ± SEM) were 17.9 ± 1.7, 32.3 ± 7.9, and 
58.0 ± 7.0 in the PTSD, NC, and LC groups, respectively. These 
peak levels occurred between 2300 and 0500 h for each of the 
PTSD and NC groups and between 0100 and 0500 h for the LC 
group. The 3 groups x 13 samples ANOVA indicated that the main 
effect of "group" was significant F(2,18) = 7.52, p = .004 (Figure 2), 
and the group x time of day interaction F(6.93,62.36)  = 4.26, 
p = .001 was significant (Figure 1). Post hoc testing of the group x 
time of day interaction confirms that the NC group produced 
more melatonin than the PTSD group between 0100 and 0500 h, 
whereas the LC group produced more melatonin than either the 
NC or PTSD groups between 2300 and 0700 h.
The significant main effect of group (Figure 2) indicated that 
the mean 24-h melatonin production was higher in the LC group 
than the PTSD and NC groups.
Sleep Data
Posttraumatic Stress Disorder Participants With the 
Best and Worst Sleep
To sustain optimum health daily sleep should involve 
approximately 8 h in bed, a regular bedtime, and normal sleep 
efficiency (80 to 90%). To achieve this sleep quality, sleep latency 
should be low (generally less than 10–15 min) with minimum 
WASO, and only a few sleep episodes (44).
The sleep data for all three groups (PTSD, NC, and LC) are 
illustrated in Supplementary Data Table 2.
Participant 2 had the worst sleep of the PTSD group while 
participant 6 had the best sleep of this group. Participant 2 
averaged about 428 min (7 h and 8 min) in bed of which only 
318 min (5 h and 18 min) were sleep. His mean WASO was very 
high (89 min) and his sleep efficiency was low (78.10%). He also 
averaged a very high number of sleep episodes (36), indicating 
extremely fractured sleep. This participant was not taking 
medications that facilitate sleep.
In contrast to participant 2, participant 6 had an average of 456 
min (7 h and 36 min) of daily nocturnal sleep. His sleep average 
efficiency was 94%, and his average sleep latency and WASO 
were 11 min and 28 min, respectively. His average number of 
sleep episodes was 14 (upper normal range).
On average, participant 2 took about 19 min longer to fall 
asleep than participant 6. Participant 2 also spent about 60 min 
longer awake after initial sleep onset and had about 23 more 
sleep episodes each night than participant 6. The other PTSD 
participants (numbers 1, 3, 4, 5, and 7) had sleep quality that was 
intermediate between the extremes of participants 2 and 6 in all 
of these parameters.
Normal Control Participants With the Best  
and Worst Sleep
Participant 8 had the worst sleep of the NC group while 
participant 10 had the best sleep of this group.
Participant 8 reported that his sleep was compromised 
because he was studying in the evenings. His average daily time 
in bed was 400 min, resulting in 324 min (5 h and 24 min) of 
sleep. His sleep efficiency was quite low at 72%. While his average 
fiGURe 1 | Mean melatonin concentrations (pg/ml) sampled over a 24-h 
period for each of the three groups: posttraumatic stress disorder (PTSD), 
normal controls (NC), and light controlled (LC). Significant differences 
occurred during physiologic night (2300 to 0700 h). Shaded symbols indicate 
values that are significantly (p < 0.05) different between groups: the time of 
day data points where NC and LC demonstrate higher melatonin levels than 
PTSD are indicated with blackened circles (NC) or blackened triangles (LC), 
respectively. All values are means ± SEM.
fiGURe 2 | Mean melatonin concentration (pg/ml) for each of three groups: 
posttraumatic stress disorder (PTSD), normal controls (NC), and light 
controlled (LC). All values are means ± SEM.
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sleep latency 17 min. He averaged about 26 sleep episodes per 
night, reflecting significantly fractured sleep.
Participant 10 averaged about 533 min (8 h and 53 min) in 
bed, resulting in an average of 497 min (8 h and 17 min) of sleep. 
His average sleep efficiency was just over 93%, while his sleep 
latency and WASO were about 19 and 24 min respectively. His 
average number of sleep episodes was about 10 per night and 
within normal limits.
On average, participant 10 achieved about 133 min (2 h 
and 13 min) more daily time in bed and achieved 173 min (2 h 
and 53 min) more sleep than participant 8. Participant 10 also 
had about a 21% higher sleep efficiency than participant 8. On 
average, participant 8 took about 2 min longer to fall, spent about 
68 min longer awake after initial sleep onset, and had about 16 
more sleep episodes each night than participant 10. The other 
NC participants (numbers 9, 11, 12, 14, and 15) had sleep quality 
intermediate between the extremes of participants 8 and 10 in all 
of these parameters.
Light Controlled Participants With the Worst and 
Best Sleep
Participant 12A had the worst sleep of the LC group, while 
participant 1A had the best sleep of this group.
Participant 12A had an average bedtime of 0005 h. He 
averaged about 406 min (6 h and 46 min) in bed, resulting 
in an average of 379 min (6 h and 19 min) of daily sleep. His 
average sleep efficiency was just over 93%, while his sleep 
latency and WASO were about 10 and 18 min respectively. 
His average number of sleep episodes was about 10 per night 
and normal.
Participant 1A had an average bedtime of 2301 h. He averaged 
about 568 min (9 h and 28 min) in bed, resulting in an average 
of 513 min (8 h and 33 min) of daily sleep. His average sleep 
efficiency was about 91%, while his sleep latency and WASO 
were about 9 and 43 min respectively. His average number of 
sleep episodes was about 16 per night, which was in the high-
normal range.
On average, participant 1A achieved about 162 min (2 h and 
42 min) more daily time in bed than participant 12A, achieved 
134 min (2 h and 14 min) more sleep than participant 12A and 
had a similar sleep efficiency (about 91 vs. 93%) as participant 
12A. Both participant 1A and 12A had very similar sleep 
latencies (9 vs. 10 min). Participant 1A had a higher average 
WASO than participant 12A (43 min versus 88 min) and a 
higher average number of daily sleep episodes (16 versus 10) 
reflecting lower sleep pressure in participant 1A, since he 
was well rested. The other LC participants (numbers 6A, 7A, 
8A, 10A, and 11A) had a sleep quality that was intermediate 
between the extremes of participants 1A and 12A in all of 
these parameters.
Each of the sleep parameters shown in Supplementary 
Data Table 2 were analyzed by three groups x 7 days repeated-
measures analysis of variance. There were no group differences in 
any parameter, although there were some differences across days 
of the week, indicating that all three groups exhibited normal 
weekend sleep behaviors of later bed times and arise times, and 
increased sleep minutes.
DiSCUSSioN
This is the first study to measure salivary melatonin secretion 
over a 24 h period in military PTSD cases versus matched 
controls. The melatonin profile curve in the PTSD group showed 
a blunted nocturnal peak and lower total quantity of melatonin 
production relative to the healthy control groups (NC and LC). 
By contrast, there was little difference in the sleep parameters 
assessed between the three groups.
Since six of seven PTSD participants were either on sleeping 
medications or anxiolytics that are known to facilitate sleep, the 
PTSD group sleep characteristics were better than expected. 
Two participants in the NC group had multiple nights with 
bedtimes ranging from 0130 to 0330 h, which decreased the 
average quality of the NC group sleep. The LC group (based 
in the high arctic) were restricted to quarters after 2000 h for 
safety due to the presence of polar bears around the CFS Alert 
Station; hence, they avoided exposure to outdoor 24-7 daylight 
prior to bedtime. Consequently, their sleep-wake was better 
than we have measured previously in other participants at 
CFS Alert during arctic summer (42). The delays in bedtime 
and arise time that were evident in Saturday and Sunday (for 
all three groups) simply reflected normal weekend behavior in 
that there was no obligation to report to work on Saturday or 
Sunday mornings.
Notwithstanding the similarity in sleep hygiene across the 
three groups, there were significant differences in nocturnal 
melatonin production between these groups. Both the NC and 
PTSD groups produced significantly less overall daily melatonin 
than the LC group (Figure 2). Despite the fact that six of the 
seven PTSD participants were on medications known to counter 
insomnia, it is apparent these sleeping medications did not restore 
the levels of endogenous melatonin for this group. The LC group 
would normally have had access to the outdoors in the arctic 
summer evening, which would have suppressed their melatonin, 
thus delaying their sleep pressure and hence their bedtime, 
causing difficulty to arise at their normal time the following 
morning. In this instance, the lack of access to the outdoors 
precluded the suppression of melatonin that we have seen 
previously in personnel stationed at CFS Alert during the arctic 
summer. The amplitude of the nocturnal surge of melatonin in 
the LC group (Figure 1) was quite normal and very similar to the 
melatonin profiles that we have measured in the lower latitudes 
across Canada (45). In contrast, the amplitude of the melatonin 
rhythm in each of NC and PTSD groups is significantly lower. In 
the case of the NC group, the lower amplitudes were probably 
related to the sleep behaviors of these participants, several of 
whom had substantially later bedtimes and likely late evening 
light exposure as a result.
In the PTSD group, the markedly lower amplitude of the 
nocturnal surge was likely associated with a pathophysiological 
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response to their PTSD and may signify an inability to maintain 
an circadian sleep-wake rhythm (30, 46). The duration of the 
nocturnal surge of endogenous melatonin in the LC group ranges 
from about 2100 to 0900 h, and is also quite typical and similar to 
what we have previously measured. In contrast the duration of the 
nocturnal surge of endogenous melatonin for the NC and PTSD 
groups was shortened. The shortened duration of the nocturnal 
melatonin surge of the NC group was likely due to the nocturnal 
exposure to light (of the subjects who had delayed bedtimes) 
(47, 48). Similar to the reduced amplitude of melatonin, the 
shortened duration of the nocturnal melatonin surge of the 
PTSD group was likely a direct consequence of their PTSD as 
their sleep behaviors were generally in the normal range due to 
sleep facilitation medications and thus did not have late evening 
light exposure (30, 46). Our findings of blunted melatonin 
production in PTSD, are consistent with those of MacFarlane 
et al. (30) and may explain the findings of Seyffert and Gettey 
(38) that supplementary bedtime melatonin was helpful in sleep 
restoration and a reduction of symptoms in their case study 
of a veteran with PTSD. Pharmacotherapy, usually selective 
serotonin reuptake inhibitors (SSRIs), and psychotherapy, 
such as cognitive-behavioral therapy, are regarded as the first-
line treatments for military PTSD (17). However, treatment-
refractory PTSD, a more severe form of the illness, has low rates 
of response or remission, even after an adequate trial of SSRI 
therapy (16). Thus, finding alternatives to SSRIs for treatment of 
PTSD is imperative to relieve the suffering associated with this 
disorder (49)
Melatonin production typically declines with age (50), 
and more so in neurodegenerative diseases, such as dementia 
(51). Deficiency in the production of endogenous melatonin 
that results in specific functional losses are improved by 
supplementation with exogenous melatonin (52). There is ample 
evidence of reduced endogenous melatonin in various types 
of cardiac diseases (53–57), fibromyalgia (51, 58), neuralgia 
(58), migraine (59, 60), epilepsy (61, 62), Menières disease 
(63), various cancers (64, 65), attention-deficit hyperactivity 
disorder (66), recurrent depression (67), and bipolar disorder 
(68). Agorastos and Lindhorst describe potential pleiotropic 
benefits of melatonergic treatments to remediate problems 
with chronodisruption, hypothalamic pituitary adrenal-axis 
dysfunction, sympathoadrenal and autonomic dysregulation, 
neuroimmunomodulation, oxidative stress, brain injury, 
cognitive function, memory and neurocircuitry, mood and 
anxiety disorders (32). The work reported here indicates that 
PTSD should be added to this evolving list of disorders/diseases 
that result in blunted production of endogenous melatonin, 
and work investigating the efficiency of supplementation with 
exogenous melatonin in PTSD sufferers should be undertaken 
soonest. There is also recent evidence that long-chain 
polyunsaturated fatty acids can be beneficial in attenuating PTSD 
symptomology (69). These and other antioxidant strategies for 
treating PTSD should also be investigated.
The results of this vanguard study must be interpreted 
within the context of its limitations. We recognize that this 
study suffers from a small sample size, and that larger military 
cohort studies are required to expand and more conclusively 
confirm these initial findings. However, even with a modest 
sample size of seven PTSD cases, this preliminary evidence 
is quite compelling with respect to the dramatically reduced 
levels of melatonin in the PTSD cohort. Similarly, our military 
control sample was not ideal, since a military career and 
operational requirements impacted the sleep/wake cycle of 
these individuals. Future studies involving military populations 
must recognize that the less than ideal sleep habits often 
observed in serving military members may influence or even 
confound their results for sleep parameters. Thus, investigators 
may consider, as we did, strictly controlling nocturnal light 
exposure, imposing daily bedtime deadlines and encouraging 
sufficient daily time in bed to obtain optimal results for 
melatonin production and calculation of DLMO.
CoNCLUSioN
Our findings reveal severely blunted nocturnal melatonin 
secretion in those individuals with military-related PTSD. Based 
upon these findings, further investigations through preclinical 
research and clinical interventional studies are warranted. This 
may include methodologically robust prospective randomized 
controlled studies, assessing the efficacy of melatonin 
treatment strategies in the prevention and/or treatment of 
PTSD. Given the potential pleiotropic benefits of melatonergic 
therapies to remediate problems with chronodisruption and 
neuroimmunomodulation, melatonin treatment could provide a 
potentially promising therapeutic approach with beneficial effects 
in the management of PTSD and trauma-related syndromes and 
comorbidities. In particular, therapeutic doses of melatonin may 
be beneficial as a complementary or alternative approach in those 
subgroups of combat veterans with severe sleep abnormalities and 
who are refractory to commonly employed psychotherapeutic 
and/or pharmacological options.
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